0000000000165044

AUTHOR

Aleksander Krag

showing 12 related works from this author

Fibrosis is not just fibrosis - basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury

2016

BACKGROUND: While morphological patterns differ, the molecular phenotype of liver fibrosis is considered a stereotypical response to chronic liver injury. However, with different cellular triggers and networks regulating fibrosis, the molecular responses of the injured liver may not be identical.AIM: To investigate whether differences in extracellular matrix (ECM) composition of the liver during fibrogenesis in two seemingly similar types of viral hepatitis could be reflected by differences in ECM turnover.METHODS: Utilising a cross-sectional design, we measured specific ECM protein fragments in plasma from 197 chronic hepatitis B (CHB) patients and 403 chronic hepatitis C (CHC) patients ma…

AdultLiver CirrhosisMale0301 basic medicinePathologymedicine.medical_specialtyInflammationMatrix metalloproteinaseBasement MembraneExtracellular matrix03 medical and health sciencesHepatitis B Chronic0302 clinical medicineFibrosisJournal ArticlemedicineHumansPharmacology (medical)Basement membraneExtracellular Matrix ProteinsHepatologybusiness.industryGastroenterologyHepatitis CHepatitis C ChronicMiddle AgedHepatitis Bmedicine.diseaseMatrix MetalloproteinasesExtracellular MatrixCross-Sectional Studies030104 developmental biologymedicine.anatomical_structureBiochemistryFemale030211 gastroenterology & hepatologyCollagenmedicine.symptomViral hepatitisbusinessBiomarkersAlimentary Pharmacology & Therapeutics
researchProduct

Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation

2019

Background & Aims Alpha-1 antitrypsin deficiency (AATD) is among the most common genetic disorders. Severe AATD is caused by a homozygous mutation in the SERPINA1 gene that encodes the Glu342Lys substitution (called the Pi*Z mutation, Pi*ZZ genotype). Pi*ZZ carriers may develop lung and liver diseases. Mutation-associated lung disorders have been well studied, but less is known about the effects in liver. We assessed the liver disease burden and associated features in adults with this form of AATD. Methods We collected data from 554 Pi*ZZ adults (403 in an exploratory cohort, 151 in a confirmatory cohort), in 9 European countries, with AATD who were homozygous for the Pi*Z mutation, and 234…

Liver CirrhosisMale0301 basic medicineALTLiver diseasechemistry.chemical_compound0302 clinical medicineLiver Function TestsRisk FactorsGenotypeRare Liver DiseaseAlpha 1-antitrypsin deficiencyHomozygoteAge FactorsGastroenterologyMiddle AgedEuropeEditorial CommentaryPhenotypemedicine.anatomical_structureLiverElasticity Imaging TechniquesFemale030211 gastroenterology & hepatologyTEAdultmedicine.medical_specialty610Mice Transgenic03 medical and health sciencesSex Factorsalpha 1-Antitrypsin DeficiencyInternal medicinemedicinePiAnimalsHumansGenetic Predisposition to DiseaseASTAgedLungHepatologyTriglyceridebusiness.industryLipid Metabolismmedicine.diseaseFatty Liver030104 developmental biologyEndocrinologychemistryCase-Control Studiesalpha 1-AntitrypsinMutationSteatosisTransient elastographybusinessGastroenterology
researchProduct

Corrigendum to ‘Baveno VII – Renewing consensus in portal hypertension’ [J Hepatol (2022) 959-974]

2022

Porta hypertensionHepatologyJournal of Hepatology
researchProduct

Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases

2022

Population screening; Liver fibrosis; Early diagnosis Cribratge de població; Fibrosi hepàtica; Diagnòstic precoç Cribado de población; Fibrosis hepática; Diagnóstico precoz Cirrhosis, highly prevalent worldwide, develops after years of hepatic inflammation triggering progressive fibrosis. Currently, the main etiologies of cirrhosis are non-alcoholic fatty liver disease and alcohol-related liver disease, although chronic hepatitis B and C infections are still major etiological factors in some areas of the world. Recent studies have shown that liver fibrosis can be assessed with relatively high accuracy noninvasively by serological tests, transient elastography, and radiological methods. Thes…

Liver Cirrhosismedicine.medical_specialtyCirrosi hepàtica - DiagnòsticCirrhosisFibrosiBiopsy:enfermedades del sistema digestivo::enfermedades hepáticas::cirrosis hepática [ENFERMEDADES]Population:Digestive System Diseases::Liver Diseases::Liver Cirrhosis [DISEASES]:Otros calificadores::/diagnóstico [Otros calificadores]DiseaseFetge -- Malalties:Diagnosis::Diagnostic Techniques and Procedures::Mass Screening [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]AsymptomaticGastroenterologyGlobal Burden of DiseaseLiver diseaseHepatitis B ChronicSDG 3 - Good Health and Well-beingLiver Function TestsNon-alcoholic Fatty Liver DiseaseRisk FactorsFibrosisInternal medicinePrevalenceCribatge (Medicina):Other subheadings::/diagnosis [Other subheadings]:diagnóstico::técnicas y procedimientos diagnósticos::cribado sistemático [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]HumansMass ScreeningMedicineeducationliver fibrosiseducation.field_of_studyHepatologybusiness.industryFatty liverCirrosiHepatitis C Chronicmedicine.diseaseEarly DiagnosisLiverDisease ProgressionElasticity Imaging Techniquesmedicine.symptomTransient elastographybusinessHepatology
researchProduct

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 tria…

2019

© 2019 Elsevier Ltd. All rights reserved.

MaleBiopsyClinical Trial Phase IIIAdministration Oral030204 cardiovascular system & hematologyChronic liver diseaseSettore MED/04Biomarkers/analysisGastroenterologychemistry.chemical_compound0302 clinical medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D013485Liver Function TestsNon-alcoholic Fatty Liver DiseaseClinical endpointMedicine030212 general & internal medicine610 Medicine & healthChenodeoxycholic Acid/administration & dosageeducation.field_of_studyLiver Function TestResearch Support Non-U.S. Gov'tFatty liverObeticholic acidNASH OBETICHOLIC ACIDGeneral Medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D052061Middle AgedMulticenter Study/dk/atira/pure/researchoutput/pubmedpublicationtype/D016448Randomized Controlled TrialAdministrationFemale/dk/atira/pure/researchoutput/pubmedpublicationtype/D016449Administration Oral; Biomarkers; Biopsy; Chenodeoxycholic Acid; Double-Blind Method; Female; Humans; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver DiseaseHumanOralmedicine.medical_specialtyPopulationPlaceboChenodeoxycholic Acid03 medical and health sciencesResearch Support N.I.H. ExtramuralDouble-Blind MethodInternal medicineJournal ArticleHumans/dk/atira/pure/researchoutput/pubmedpublicationtype/D017428educationIntention-to-treat analysisbusiness.industryBiomarkerInterim analysismedicine.diseaseNon-alcoholic Fatty Liver Disease/drug therapychemistryHuman medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D016428businessBiomarkersAdministration; Oral; Biomarkers; Biopsy; Chenodeoxycholic Acid; Double-Blind Method; Female; Humans; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver Disease
researchProduct

Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease

2021

Background: The Baveno VI consensus proposed a dual liver stiffness (LS) by transient elastography threshold of <10 and >15 kPa for excluding and diagnosing compensated advanced chronic liver disease (cACLD) in the absence of other clinical signs. Herein, we aimed to validate these criteria in a real-world multicentre study. Methods: We included 5,648 patients (mean age 51 ± 13 years, 53% males) from 10 European liver centres who had a liver biopsy and LS measurement within 6 months. We included patients with chronic hepatitis C (n = 2,913, 52%), non-alcoholic fatty liver disease (NAFLD, n = 1,073, 19%), alcohol-related liver disease (ALD, n = 946, 17%) or chronic hepatitis B (n = 716…

0301 basic medicineAlcoholic liver diseasemedicine.medical_specialtyCirrhosis[SDV]Life Sciences [q-bio]Chronic liver diseaseAsymptomaticGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineInternal medicineNAFLDmedicineViral hepatitis10. No inequalityPortal hypertensionComputingMilieux_MISCELLANEOUSCirrhosiHepatologymedicine.diagnostic_testbusiness.industryFatty liverAlcoholic liver diseasemedicine.disease3. Good health030104 developmental biologyFibroscanCirrhosisLiver biopsyFIB-4030211 gastroenterology & hepatologymedicine.symptomTransient elastographybusinessViral hepatitis.
researchProduct

Baveno VII – Renewing consensus in portal hypertension

2022

To expand on the work of previous meetings, a virtual Baveno VII workshop was organised for October 2021. Among patients with compensated cirrhosis or compensated advanced chronic liver disease (cACLD – defined at the Baveno VI conference), the presence or absence of clinically significant portal hypertension (CSPH) is associated with differing outcomes, including risk of death, and different diagnostic and therapeutic needs. Accordingly, the Baveno VII workshop was entitled “Personalized Care for Portal Hypertension”. The main fields of discussion were the relevance and indications for measuring the hepatic venous pressure gradient as a gold standard, the use of non-invasive tools for the …

recommendationLiver CirrhosisCirrhosiHepatologydecompensationtreatmentdiagnosisEsophageal and Gastric VaricesPortal PressurediagnosiCirrhosisHypertension PortalrecommendationsHypertensionHumansElasticity Imaging TechniquesCirrhosis; decompensation; diagnosis; recommendations; treatmentPortalCirrhosis; decompensation; diagnosis; recommendations; treatment; Humans; Liver Cirrhosis; Portal Pressure; Elasticity Imaging Techniques; Esophageal and Gastric Varices; Hypertension Portal
researchProduct

Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification.

2018

Background & Aims: Controlled attenuation parameter (CAP) is a novel non-invasive measure of hepatic steatosis, but it has not been evaluated in alcoholic liver disease. Therefore, we aimed to validate CAP for the assessment of biopsy-verified alcoholic steatosis and to study the effect of alcohol detoxification on CAP. Methods: This was a cross-sectional biopsy-controlled diagnostic study in four European liver centres. Consecutive alcohol-overusing patients underwent concomitant CAP, regular ultrasound, and liver biopsy. In addition, we measured CAP before and after admission for detoxification in a separate single-centre cohort. Results: A total of 562 patients were included in the s…

MaleAlcoholic liver diseasemedicine.medical_treatmentBiopsyGastroenterologyCohort StudiesSensitivity0302 clinical medicineInterquartile rangeRisk FactorsAlcohol detoxificationNon-invasiveSteatohepatitisUltrasonography2. Zero hungerMetabolic Syndromemedicine.diagnostic_testAlcohol AbstinenceFatty liverAlcohol detoxificationDiagnostic testMiddle Aged3. Good healthAlcoholismLiver030220 oncology & carcinogenesisLiver biopsyControlled attenuation parameterSpecificityElasticity Imaging Techniques030211 gastroenterology & hepatologyFemaleFatty Liver AlcoholicAdultmedicine.medical_specialty03 medical and health sciencesPredictive Value of TestsFatty liverInternal medicinemedicineHumansFibroScanHepatologybusiness.industryAlcoholic liver diseasemedicine.diseaseCross-Sectional StudiesConcomitantSteatohepatitisSteatosisbusinessJournal of hepatology
researchProduct

Europäische Studie: Heterozygoter Alpha-1-Antitrypsinmangel (Pi*MZ) führt zu einem intermediären Leber-Phänotyp

2020

Zeitschrift für Gastroenterologie
researchProduct

Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential an…

2016

There are no approved treatments for liver fibrosis. To aid development of antifibrotic therapies, noninvasive biomarkers that can identify patients with progressive fibrosis and that permit monitoring of the response to antifibrotic therapy are much needed. Samples from a phase II antifibrotic trial of the glitazone farglitazar in patients with advanced hepatitis C, with matched follow-up liver biopsies, and from a phase III study of balaglitazone in patients with late-stage Type 2 diabetes (BALLET study) were analyzed for serological Pro-C3 levels in conjunction with other disease parameters. In the farglitazar study, a predefined cutoff value for Pro-C3 as a selection criterion led to t…

Liver CirrhosisMale0301 basic medicineNonalcoholic steatohepatitisPathologymedicine.medical_specialtyPhysiologyLiver fibrosisType 2 diabetesSerology03 medical and health sciencesCollagen formation0302 clinical medicineFibrosisSerum biomarkersPhysiology (medical)Journal ArticlemedicineHumansOxazolesType III collagenHepatologybusiness.industryPatient SelectionGastroenterologyMiddle Agedmedicine.disease3. Good healthCollagen Type III030104 developmental biologyQuinazolinesTyrosineFemaleThiazolidinediones030211 gastroenterology & hepatologybusinessBiomarkersAmerican Journal of Physiology-Gastrointestinal and Liver Physiology
researchProduct

Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia

2019

Background & Aims: Non-alcoholic fatty liver disease and alcohol-related liver disease pose an important challenge to current clinical healthcare pathways because of the large number of at-risk patients. Therefore, we aimed to explore the cost-effectiveness of transient elastography (TE) as a screening method to detect liver fibrosis in a primary care pathway. Methods: Cost-effectiveness analysis was performed using real-life individual patient data from 6 independent prospective cohorts (5 from Europe and 1 from Asia). A diagnostic algorithm with conditional inference trees was developed to explore the relationships between liver stiffness, socio-demographics, comorbidities, and hepati…

0301 basic medicinemedicine.medical_specialtyTransient elastographyPopulationLiver fibrosisDisease03 medical and health sciencesLiver disease0302 clinical medicineFibrosisInternal medicinemedicineeducationeducation.field_of_studyAlcohol-related liver diseaseHepatologybusiness.industryFatty liverCost-effectiveness analysismedicine.disease3. Good health030104 developmental biologyStratified screening030211 gastroenterology & hepatologyTransient elastographybusinessHepatic fibrosisNon-alcoholic fatty liver disease
researchProduct

Is the Total Amount as Important as Localization and Type of Collagen in Liver Fibrosis Attributable to Steatohepatitis?

2020

Is liver fibrosis just liver fibrosis? Or do the subtype of collagen, its spatial localization in the liver, its cell of origin, and the time point at which it is synthesized also matter? It is important, since the various collagen subtypes hold different informative values regarding reparative processes in the liver, and as collagens have also emerged as important signaling molecules (1). Novel data have challenged our perception of liver fibrosis and collagens, which may have important implications regarding the development of new biomarkers and anti-fibrotic interventions. The traditional histological analysis of liver biopsies using histochemical collagen stains, such as the Masson's Tr…

Liver Cirrhosis0303 health sciencesPathologymedicine.medical_specialtyHepatologybusiness.industryLiver fibrosismedicine.diseaseFatty Liver03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesismedicineAnimalsHumansCollagenSteatohepatitisbusiness030304 developmental biology
researchProduct